HBOT Conversations:
Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy
Subscribe. Join the discussion. Share the hope.
Listen to or Watch the HBOT Conversations Podcast
Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:
Watch the HBOT Conversations Podcast
Subscribe Now, It’s Free !
Recent HBOT News
Right cardiac intracavitary metastases from a primary intracranial myxofibrosarcoma.
Abstract: Primary intracranial myxofibrosarcoma is exceedingly rare, with less than 10 cases published. We present a case of a 23-year-old man with previous history of a primary low grade myxofibrosarcoma of the left parietal-occipital convexity resected in March...
Clinical Trial – Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy
Diabetes kidney disease is a leading cause for end stage renal disease in the western world.
To date no treatment that can reverse renal damage exists.
Chronic hypoxia is one of the major key insults affecting the diabetic kidney, and many of
the new treatments under study focus on it’s consequences, but no treatment can improve the
hypoxia as both increased renal perfusion and decreased renal perfusion may be associated
with it’s worsening. Hyperbaric oxygen therapy (HBOT) can improve renal hypoxia by increasing
partial pressure of dissolved (non-hemoglobin-bound) oxygen without affecting it’s demand.
HBOT also recruits tissue and peripheral progenitors and supplies the optimal environment
crucial for their proliferation and for tissue repair. Hyperbaric oxygen treatment was known
for years as an effective treatment for diabetic ulcers. Recent trials have shown great
impact on brain lesions (in diabetic and non-diabetic patients) it is now the time to
evaluate the effect of HBOT on the diabetic kidney.
Clinical Trial – Cardiac Output Changes During Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Cesarean Section
Spinal block leads to the reduction of systemic vascular resistance (SVR) which may effect
the cardiac output. Ngan Kee et al. has showed that spina block with 0.5% hyperbaric
bupivacaine for Cesarean section combined with intravenous infusion norepinephrine had higher
cardiac output than those who received phenylephrine